Zacks: Immune Design Corp (IMDZ) Receives Average Recommendation of “” from Analysts
Shares of Immune Design Corp (NASDAQ:IMDZ) have received an average broker rating score of 0.00 () from the four analysts that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.
Analysts have set a twelve-month consensus price target of $17.50 for the company and are forecasting that the company will post ($0.62) earnings per share for the current quarter, according to Zacks. Zacks has also given Immune Design Corp an industry rank of 96 out of 265 based on the ratings given to related companies.
IMDZ has been the subject of a number of research reports. Jefferies Group LLC increased their price target on Immune Design Corp from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, March 8th. Zacks Investment Research cut Immune Design Corp from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 17th.
Your IP Address:
Immune Design Corp (NASDAQ:IMDZ) opened at 7.20 on Tuesday. Immune Design Corp has a 12-month low of $4.50 and a 12-month high of $16.94. The firm’s 50-day moving average price is $5.64 and its 200 day moving average price is $6.54. The company’s market capitalization is $183.16 million.
Immune Design Corp (NASDAQ:IMDZ) last announced its quarterly earnings results on Tuesday, March 7th. The company reported ($0.57) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.57). Immune Design Corp had a negative return on equity of 50.92% and a negative net margin of 415.05%. On average, analysts expect that Immune Design Corp will post ($2.44) earnings per share for the current year.
In related news, Director Lewis W. Coleman sold 10,000 shares of the stock in a transaction on Thursday, December 22nd. The stock was sold at an average price of $6.20, for a total value of $62,000.00. Following the completion of the sale, the director now directly owns 40,000 shares in the company, valued at $248,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 15,582 shares of company stock valued at $91,864 over the last 90 days. 42.90% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of IMDZ. Alyeska Investment Group L.P. increased its stake in Immune Design Corp by 0.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 167,493 shares of the company’s stock worth $921,000 after buying an additional 1,334 shares during the last quarter. State Street Corp increased its stake in Immune Design Corp by 8.3% in the fourth quarter. State Street Corp now owns 237,563 shares of the company’s stock worth $1,311,000 after buying an additional 18,115 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Immune Design Corp by 10.2% in the third quarter. JPMorgan Chase & Co. now owns 271,802 shares of the company’s stock worth $2,060,000 after buying an additional 25,127 shares during the last quarter. Sphera Funds Management LTD. increased its stake in Immune Design Corp by 32.7% in the third quarter. Sphera Funds Management LTD. now owns 203,000 shares of the company’s stock worth $1,539,000 after buying an additional 50,000 shares during the last quarter. Finally, Monashee Investment Management LLC bought a new stake in Immune Design Corp during the third quarter worth $379,000. Institutional investors and hedge funds own 53.07% of the company’s stock.
Immune Design Corp Company Profile
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related companies with MarketBeat.com's FREE daily email newsletter.